Setback
Ekso's parent company, renamed ChronoScale and moving into cloud computing, said it would sell the Ekso exoskeleton business.
A delay, pause or setback
What the source says
“the board committed to divesting the unit on May 29 and publicly announced the decision on June 4”
What it means
Medical exoskeletons, from Lifeward (ReWalk), Wandercraft, Ekso Bionics (owned by Wandercraft since Oct 2026), is at stage 5 of 5 on our ladder: regulator-cleared or mass market. A setback stays on the record next to the milestones; the stage moves down only when the rules say so.
Human help: A staff member rides along, ready to stop it.
More on Medical exoskeletons
- Wandercraft bought Ekso Bionics from ChronoScale and said it would keep supporting Atalante X, EksoNR, Eve and Indego Personal. The price was not disclosed.
- Wandercraft said the FDA cleared Eve, a self-balancing exoskeleton for personal use, for adults with spinal cord injuries at any level, used with a trained companion.
- The FDA cleared the ReWalk 7 Personal Exoskeleton from Lifeward (510(k) K241822) for indoor and outdoor walking, including stairs and curbs.
- Medicare set a payment rate for personal exoskeletons for home use, starting with the ReWalk Personal and the Indego Personal.
- Ekso Bionics bought the Indego exoskeleton business from Parker Hannifin for $10 million.
- The FDA cleared the Ekso GT for use in rehab centres with people who have had a stroke or a spinal cord injury.